Immunic (NASDAQ:IMUX) Downgraded to “Sell” at StockNews.com

Immunic (NASDAQ:IMUX) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Friday.

Immunic Stock Performance

Immunic stock traded up $0.02 during mid-day trading on Friday, reaching $1.32. 215,951 shares of the company were exchanged, compared to its average volume of 584,235. Immunic has a twelve month low of $0.95 and a twelve month high of $3.11. The firm’s 50-day simple moving average is $1.29 and its two-hundred day simple moving average is $1.28. The firm has a market cap of $118.71 million, a PE ratio of -0.63 and a beta of 2.07.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings data on Thursday, February 22nd. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.03. As a group, equities research analysts anticipate that Immunic will post -1 EPS for the current year.

Hedge Funds Weigh In On Immunic

Several hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. increased its position in Immunic by 21.2% during the first quarter. JPMorgan Chase & Co. now owns 13,649 shares of the company’s stock worth $154,000 after buying an additional 2,387 shares in the last quarter. Rhumbline Advisers boosted its holdings in Immunic by 30.6% in the first quarter. Rhumbline Advisers now owns 22,122 shares of the company’s stock valued at $250,000 after acquiring an additional 5,182 shares during the last quarter. Northern Trust Corp boosted its holdings in Immunic by 3.0% in the first quarter. Northern Trust Corp now owns 188,148 shares of the company’s stock valued at $2,126,000 after acquiring an additional 5,553 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Immunic by 2.5% during the second quarter. BlackRock Inc. now owns 377,503 shares of the company’s stock worth $948,000 after purchasing an additional 9,061 shares in the last quarter. Finally, Two Sigma Investments LP lifted its stake in shares of Immunic by 3.4% during the first quarter. Two Sigma Investments LP now owns 290,668 shares of the company’s stock worth $433,000 after purchasing an additional 9,603 shares in the last quarter. 51.82% of the stock is owned by hedge funds and other institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.